A Study to Tailor Advance Directives
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00121004|
Recruitment Status : Completed
First Posted : July 19, 2005
Last Update Posted : September 5, 2013
|Condition or disease||Intervention/treatment|
|Dementia Persistent Vegetative State Terminally Ill||Behavioral: Advance Directive Selection|
The purpose of this study is to assess whether patients will execute an advance directive which offers a limited trial of life-sustaining therapy in non-terminal illness, declines life-sustaining therapy or artificial nutrition in advanced dementia, or declines life-sustaining therapy in general. Advance directives (ADs) as currently drafted have been questioned since they have not had much effect on end-of-life care. However, the reason for the lack of success may be simply that they rarely apply. Traditional ADs, which are limited to terminal illness or persistent vegetative states, are difficult to apply to the more common cases of critical illness in the setting of potentially reversible disease and advanced dementia, which are often not recognized as terminal. In addition, terminal ADs are drafted too narrowly for patients who do not wish for life-sustaining therapy regardless of condition.
Patients may execute either AD at the conclusion of the survey. This research has the potential to demonstrate widely reproducible methods on which more precise advance planning can be based and thereby improve end-of-life care.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Study to Tailor Advance Directives|
|Study Start Date :||July 2005|
|Primary Completion Date :||September 2005|
|Study Completion Date :||September 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00121004
|United States, Illinois|
|The University of Chicago|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||Elmer Abbo, M.D., Ph.D.||University of Chicago|
|Principal Investigator:||David Meltzer, M.D., Ph.D.||University of Chicago|